James H Stein1, Noah Kime2, Claudia E Korcarz1, Heather Ribaudo3, Judith S Currier4, Joseph C Delaney2,5. 1. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison (J.H.S., C.E.K.). 2. University of Washington Collaborative Health Studies Coordinating Center, Seattle (N.K., J.C.D.). 3. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA (H.R.). 4. Division of Infectious Disease, David Geffen School of Medicine at University of California, Los Angeles (J.S.C.). 5. College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg (J.C.D.).
Abstract
OBJECTIVE: To determine the effects of HIV serostatus and disease severity on endothelial function in a large pooled cohort study of people living with HIV infection and HIV- controls. Approach and Results: We used participant-level data from 9 studies: 7 included people living with HIV (2 treatment-naïve) and 4 had HIV- controls. Brachial artery flow-mediated dilation (FMD) was measured using a standardized ultrasound imaging protocol with central reading. After data harmonization, multiple linear regression was used to examine the effects of HIV- serostatus, HIV disease severity measures, and cardiovascular disease risk factors on FMD. Of 2533 participants, 986 were people living with HIV (mean 44.4 [SD 11.8] years old) and 1547 were HIV- controls (42.9 [12.2] years old). The strongest and most consistent associates of FMD were brachial artery diameter, age, sex, and body mass index. The effect of HIV+ serostatus on FMD was strongly influenced by kidney function. In the highest tertile of creatinine (1.0 mg/dL), the effect of HIV+ serostatus was strong (β=-1.59% [95% CI, -2.58% to -0.60%], P=0.002), even after covariate adjustment (β=-1.36% [95% CI, -2.46% to -0.47%], P=0.003). In the lowest tertile (0.8 mg/dL), the effect of HIV+ serostatus was strong (β=-1.90% [95% CI, -2.58% to -1.21%], P<0.001), but disappeared after covariate adjustment. HIV RNA viremia, CD4+ T-cell count, and use of antiretroviral therapy were not meaningfully associated with FMD. CONCLUSIONS: The significant effect of HIV+ serostatus on FMD suggests that people living with HIV are at increased cardiovascular disease risk, especially if they have kidney disease.
OBJECTIVE: To determine the effects of HIV serostatus and disease severity on endothelial function in a large pooled cohort study of people living with HIV infection and HIV- controls. Approach and Results: We used participant-level data from 9 studies: 7 included people living with HIV (2 treatment-naïve) and 4 had HIV- controls. Brachial artery flow-mediated dilation (FMD) was measured using a standardized ultrasound imaging protocol with central reading. After data harmonization, multiple linear regression was used to examine the effects of HIV- serostatus, HIV disease severity measures, and cardiovascular disease risk factors on FMD. Of 2533 participants, 986 were people living with HIV (mean 44.4 [SD 11.8] years old) and 1547 were HIV- controls (42.9 [12.2] years old). The strongest and most consistent associates of FMD were brachial artery diameter, age, sex, and body mass index. The effect of HIV+ serostatus on FMD was strongly influenced by kidney function. In the highest tertile of creatinine (1.0 mg/dL), the effect of HIV+ serostatus was strong (β=-1.59% [95% CI, -2.58% to -0.60%], P=0.002), even after covariate adjustment (β=-1.36% [95% CI, -2.46% to -0.47%], P=0.003). In the lowest tertile (0.8 mg/dL), the effect of HIV+ serostatus was strong (β=-1.90% [95% CI, -2.58% to -1.21%], P<0.001), but disappeared after covariate adjustment. HIV RNA viremia, CD4+ T-cell count, and use of antiretroviral therapy were not meaningfully associated with FMD. CONCLUSIONS: The significant effect of HIV+ serostatus on FMD suggests that people living with HIV are at increased cardiovascular disease risk, especially if they have kidney disease.
Entities:
Keywords:
arteries; cardiovascular diseases; creatinine; human immunodeficiency virus; viremia
Authors: Andrew C Philpott; Eva Lonn; Lawrence M Title; Subodh Verma; Jean Buithieu; Francois Charbonneau; Todd J Anderson Journal: Am J Cardiol Date: 2009-04-08 Impact factor: 2.778
Authors: Daniel R Drozd; Mari M Kitahata; Keri N Althoff; Jinbing Zhang; Stephen J Gange; Sonia Napravnik; Greer A Burkholder; William C Mathews; Michael J Silverberg; Timothy R Sterling; Susan R Heckbert; Matthew J Budoff; Stephen Van Rompaey; Joseph A C Delaney; Cherise Wong; Weiqun Tong; Frank J Palella; Richard A Elion; Jeffrey N Martin; John T Brooks; Lisa P Jacobson; Joseph J Eron; Amy C Justice; Matthew S Freiberg; Daniel B Klein; Wendy S Post; Michael S Saag; Richard D Moore; Heidi M Crane Journal: J Acquir Immune Defic Syndr Date: 2017-08-15 Impact factor: 3.731
Authors: Heather M Johnson; Linda K Gossett; Megan E Piper; Susan E Aeschlimann; Claudia E Korcarz; Timothy B Baker; Michael C Fiore; James H Stein Journal: J Am Coll Cardiol Date: 2010-03-17 Impact factor: 24.094
Authors: Cecilia M Shikuma; Todd Seto; Chin-Yuan Liang; Kara Bennett; Victor DeGruttola; Mariana Gerschenson; James H Stein; Matthew Budoff; Howard N Hodis; Joseph A C Delaney; Debra Ogata-Arakaki; Pornpoj Pramyothin; Dominic Chow Journal: AIDS Res Hum Retroviruses Date: 2011-11-11 Impact factor: 2.205
Authors: Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton Journal: PLoS One Date: 2012-09-10 Impact factor: 3.240
Authors: Frances Wensley; Pei Gao; Stephen Burgess; Stephen Kaptoge; Emanuele Di Angelantonio; Tina Shah; James C Engert; Robert Clarke; George Davey-Smith; Børge G Nordestgaard; Danish Saleheen; Nilesh J Samani; Manjinder Sandhu; Sonia Anand; Mark B Pepys; Liam Smeeth; John Whittaker; Juan Pablo Casas; Simon G Thompson; Aroon D Hingorani; John Danesh Journal: BMJ Date: 2011-02-15